Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma

Abstract

Combination therapy with sorafenib and temsirolimus resulted in significant toxicity at higher dose levels, failed to achieve any clinical responses in genetically unselected patient population, and did not inhibit P-ERK.